Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATYR PHARMA, INC.

(LIFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

aTyr Pharma : Roth Capital Adjusts aTyr Pharma's Price Target to $21 from $20, Keeps Buy Rating

09/14/2021 | 11:55am EST


ę MT Newswires 2021
All news about ATYR PHARMA, INC.
11/30ATyr Pharma, Fujifilm Diosynth Biotechnologies Enter Manufacturing Agreement for ATYR19..
MT
11/30ATyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for ..
AQ
11/15ATyr Pharma to Present at Upcoming Investor Conferences in November
AQ
11/12ATYR PHARMA INC Management's Discussion and Analysis of Financial Condition and Result..
AQ
11/12ATyr Pharma to Present at Upcoming Investor Conferences in November
AQ
11/11HC Wainwright Adjusts aTyr Pharma's Price Target to $11 from $18, Keeps Buy Rating
MT
11/10ATyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update - Form 8..
PU
11/10ATYR PHARMA : Q3 Earnings Snapshot
AQ
11/10ATyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
AQ
11/10ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
More news
Analyst Recommendations on ATYR PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 2,52 M - -
Net income 2021 -32,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,80x
Yield 2021 -
Capitalization 239 M 239 M -
Capi. / Sales 2021 95,1x
Capi. / Sales 2022 56,7x
Nbr of Employees 42
Free-Float 97,7%
Chart ATYR PHARMA, INC.
Duration : Period :
aTyr Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATYR PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 8,61 $
Average target price 18,50 $
Spread / Average Target 115%
EPS Revisions
Managers and Directors
Sanjay S. Shukla President, Chief Executive Officer & Director
Jill M. Broadfoot Chief Financial Officer
John K. Clarke Chairman
Leslie Nangle Vice President-Research
Paul R. Schimmel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ATYR PHARMA, INC.111.08%228
MODERNA, INC.170.27%114 479
LONZA GROUP AG24.16%58 572
IQVIA HOLDINGS INC.50.86%51 638
SEAGEN INC.-16.39%26 777
CELLTRION, INC.-42.20%23 611